News & Events

Learn about what's new with CMC Biologics

CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics

News

BOTHELL, Wash., BERKELEY, Calif., and SOUTH SAN FRANCISCO, Calif., USA -- December 12, 2017 -- CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC™ technology platform to discover and develop novel biologics for the treatment of cancer, announced today they have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC™ molecules for the treatment of various human cancers.

Follow Us
Join us on LinkedIn Follow us on Twitter